CN119241632A - 雷公藤红素的类似物 - Google Patents

雷公藤红素的类似物 Download PDF

Info

Publication number
CN119241632A
CN119241632A CN202411356905.2A CN202411356905A CN119241632A CN 119241632 A CN119241632 A CN 119241632A CN 202411356905 A CN202411356905 A CN 202411356905A CN 119241632 A CN119241632 A CN 119241632A
Authority
CN
China
Prior art keywords
administration
mmol
solution
obesity
vacuo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411356905.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·马济兹克
Y·丁
K·沈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erx Pharmaceuticals Inc
Original Assignee
Erx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erx Pharmaceuticals Inc filed Critical Erx Pharmaceuticals Inc
Publication of CN119241632A publication Critical patent/CN119241632A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Filters (AREA)
CN202411356905.2A 2015-10-23 2016-10-21 雷公藤红素的类似物 Pending CN119241632A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562245356P 2015-10-23 2015-10-23
US62/245,356 2015-10-23
CN201680076127.9A CN108601751A (zh) 2015-10-23 2016-10-21 雷公藤红素的类似物
PCT/US2016/058313 WO2017070615A1 (en) 2015-10-23 2016-10-21 Analogs of celastrol

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680076127.9A Division CN108601751A (zh) 2015-10-23 2016-10-21 雷公藤红素的类似物

Publications (1)

Publication Number Publication Date
CN119241632A true CN119241632A (zh) 2025-01-03

Family

ID=58558149

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411356905.2A Pending CN119241632A (zh) 2015-10-23 2016-10-21 雷公藤红素的类似物
CN201680076127.9A Pending CN108601751A (zh) 2015-10-23 2016-10-21 雷公藤红素的类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680076127.9A Pending CN108601751A (zh) 2015-10-23 2016-10-21 雷公藤红素的类似物

Country Status (8)

Country Link
US (3) US10662218B2 (cg-RX-API-DMAC7.html)
EP (1) EP3364956A4 (cg-RX-API-DMAC7.html)
JP (3) JP7034078B2 (cg-RX-API-DMAC7.html)
CN (2) CN119241632A (cg-RX-API-DMAC7.html)
AU (3) AU2016342375B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018008103A2 (cg-RX-API-DMAC7.html)
MA (1) MA45430A (cg-RX-API-DMAC7.html)
WO (1) WO2017070615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241632A (zh) * 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
WO2017180998A2 (en) 2016-04-15 2017-10-19 Beckman Coulter, Inc. Photoactive macromolecules and uses thereof
WO2017214709A1 (en) * 2016-06-15 2017-12-21 NOISEUX, Nicolas Reagents, compositions and methods for improving viability and function of cells, tissues and organs
CN108026142B (zh) * 2016-07-04 2022-07-08 艾凯奇(厦门)生物科技有限公司 孤儿核受体Nur77的配体及其用途
CN109705187B (zh) * 2019-01-29 2021-08-20 石家庄学院 一种雷公藤红素衍生物及其制备方法与应用
CN112094313B (zh) * 2019-06-17 2023-07-04 中国科学院上海药物研究所 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途
CN112110977B (zh) * 2019-06-21 2022-02-25 中国科学院上海药物研究所 一类雷公藤红素衍生物、其制备方法及用途
CA3163593A1 (en) 2020-01-15 2021-07-22 Guangrong Zheng Therapeutic agents and methods of treatment
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
US12673106B2 (en) 2020-08-28 2026-07-07 University Of Florida Research Foundation, Incorporated Modulators of nuclear receptor subfamily 4 group A member 1 (NR4A1) and uses thereof
CN115677812B (zh) * 2022-01-18 2023-12-15 聊城大学 一类雷公藤红素衍生物及其制备方法与应用
US20250375401A1 (en) * 2022-06-21 2025-12-11 Seoul National University R&Db Foundation Pharmaceutical composition containing demethylzeylasteral for prevention or treatment of diseases caused by muscle loss
IL317983A (en) * 2022-07-15 2025-02-01 Celloram Inc History of Celestrol
EP4618998A1 (en) * 2022-11-17 2025-09-24 ERX Pharmaceuticals Inc. Celastrol salts, crystalline forms, and uses thereof
US20260191807A1 (en) * 2022-11-17 2026-07-09 Erx Pharmaceuticals Inc. Compositions and methods for treatment of prader-willi syndrome
WO2025106760A1 (en) * 2023-11-16 2025-05-22 Erx Pharmaceuticals Corporation Intranasal formulations of celastrol
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
FR2875913A1 (fr) 2004-09-29 2006-03-31 Sea On Line Sa Systeme d'alerte anti-collision installe a bord d'un vehicule marin et procede d'analyse anti-collision
ES2277568B1 (es) 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
CN101686951A (zh) 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CA2808359C (en) * 2010-08-23 2019-09-24 Suzhou Neupharma Co., Ltd. Analogs of celasterol and pharmaceutical compositions comprised thereof
EA201492184A1 (ru) 2012-05-25 2015-07-30 Берг Ллк Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета
CA2874631C (en) 2012-05-25 2022-08-30 S.P.M. Flow Control, Inc. Apparatus and methods for evaluating systems associated with wellheads
CN111529535A (zh) * 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
BR112016021985B1 (pt) * 2014-03-26 2022-08-30 The General Hospital Corporation Formulação farmacêutica
CN119241632A (zh) * 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
WO2018125812A1 (en) 2017-01-02 2018-07-05 Gauss Surgical, Inc. Tracking surgical items with prediction of duplicate imaging of items

Also Published As

Publication number Publication date
RU2018118633A (ru) 2019-11-25
BR112018008103A2 (pt) 2018-11-06
US20240190911A1 (en) 2024-06-13
JP2022017473A (ja) 2022-01-25
MA45430A (fr) 2019-05-01
JP7339992B2 (ja) 2023-09-06
CN108601751A (zh) 2018-09-28
US20210061851A1 (en) 2021-03-04
AU2024201504A1 (en) 2024-03-28
AU2022204238A1 (en) 2022-07-07
JP7034078B2 (ja) 2022-03-11
JP2023164877A (ja) 2023-11-14
EP3364956A4 (en) 2019-05-01
JP2018531289A (ja) 2018-10-25
US10662218B2 (en) 2020-05-26
WO2017070615A1 (en) 2017-04-27
AU2022204238B2 (en) 2023-12-14
US20180362575A1 (en) 2018-12-20
AU2016342375B2 (en) 2022-03-17
CA3002924A1 (en) 2017-04-27
RU2018118633A3 (cg-RX-API-DMAC7.html) 2020-02-17
EP3364956A1 (en) 2018-08-29
US11753436B2 (en) 2023-09-12
AU2016342375A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
US20240190911A1 (en) Analogs of celastrol
JP2018531289A6 (ja) セラストロールの類似体
EP3681862B1 (en) Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
KR20230159466A (ko) 구아이안계 세스퀴테르펜 유도체 및 이의 제약 용도
CN102471248A (zh) 用于递送1,3-丙二磺酸的方法、化合物和组合物
EA020198B1 (ru) N-ацетил-(r)-(-)-3-(4-аминофенил)-2-метоксипропионовая кислота, содержащая ее фармацевтическая композиция, способ лечения
EA016568B1 (ru) Способы, соединения, композиции и носители для доставки 3-амино-1-пропансульфоновой кислоты
EA023751B1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
IL291898A (en) Quinone-, hydroquinone- and naphthoquinone-analogues of vatiquinone for treatment of mitochondrial disorder diseases
JP7744689B2 (ja) 脂質代謝関連疾患の予防又は治療用化合物
JP2022507404A (ja) 眼疾患治療用のペプチド及び医薬組成物
WO2017156074A1 (en) Calpain modulators and methods of production and use thereof
WO2019053429A1 (en) CHIRAL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCEMIA
JP2024515597A (ja) ムスカリン性アセチルコリンm1受容体アンタゴニストの結晶性化合物
GB2613616A (en) New formulations
CN112218878A (zh) Ntcp抑制剂
WO2017131144A1 (ja) ビタミンd活性を有するリトコール酸誘導体
WO2024239762A1 (zh) 磷酸二酯酶4抑制剂、其药物组合物及其应用
RU2776845C2 (ru) Аналоги целастрола
CA3002924C (en) Analogs of celastrol
JP2018177738A (ja) Trpv4活性抑制剤
US20260001833A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
BR122023014342B1 (pt) Compostos análogos de celastrol, composição farmacêutica compreendendo ditos compostos e usos dos mesmos para tratar obesidade ou uma doença ou distúrbio relacionado à obesidade
WO2025252064A1 (en) Thr-beta modulator for treatment of metabolic diseases
WO2026092580A1 (en) Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination